Felix Kim

Felix Kim serves as an Associate Professor in the Department of Cancer Biology at Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, with office location at 809 BLSB, 233 S. 10th Street.

His research centers on prostate cancer biology, specifically investigating castration-resistant prostate cancer (CRPC) mechanisms and therapeutic resistance. Dr. Kim identified Sigma1 as a druggable target aberrantly expressed in prostate tumors, where it regulates lipid/protein homeostasis to support tumor growth and metastasis. His laboratory explores how Sigma1 modulators disrupt cancer cell metabolism and overcome resistance to androgen deprivation therapy, aiming to develop co-targeting strategies against primary drivers and adaptive resistance networks.

Dr. Kim maintains an active research laboratory at Thomas Jefferson University, as evidenced by his dedicated lab website, focusing on Sigma1's role in therapeutic intervention for advanced prostate cancer.